Log in

NASDAQ:ATRAAtara Biotherapeutics Stock Price, Forecast & News

$14.69
-0.62 (-4.05 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.47
Now: $14.69
$15.66
50-Day Range
$8.94
MA: $12.16
$15.50
52-Week Range
$4.52
Now: $14.69
$19.36
Volume711,000 shs
Average Volume1.76 million shs
Market Capitalization$865.98 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Read More
Atara Biotherapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATRA
CUSIPN/A
Phone650-278-8930

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.37 per share

Profitability

Net Income$-290,980,000.00

Miscellaneous

Employees321
Market Cap$865.98 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

How has Atara Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATRA shares have increased by 47.5% and is now trading at $14.69. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Atara Biotherapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atara Biotherapeutics.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Atara Biotherapeutics.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics Inc (NASDAQ:ATRA) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.41) by $0.21. View Atara Biotherapeutics' earnings history.

What price target have analysts set for ATRA?

11 equities research analysts have issued 1-year price targets for Atara Biotherapeutics' shares. Their forecasts range from $9.00 to $38.00. On average, they expect Atara Biotherapeutics' share price to reach $23.75 in the next year. This suggests a possible upside of 61.7% from the stock's current price. View analysts' price targets for Atara Biotherapeutics.

Has Atara Biotherapeutics been receiving favorable news coverage?

Headlines about ATRA stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Atara Biotherapeutics earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Atara Biotherapeutics.

Who are some of Atara Biotherapeutics' key competitors?

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include Crispr Therapeutics (CRSP), AbbVie (ABBV), Gilead Sciences (GILD), Micron Technology (MU), Amarin (AMRN), Editas Medicine (EDIT), Exelixis (EXEL), Karyopharm Therapeutics (KPTI), Advanced Micro Devices (AMD) and ImmunoGen (IMGN).

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the following people:
  • Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)
  • Mr. Utpal Koppikar, Chief Financial Officer (Age 49)
  • Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)
  • Ms. Mina Kim, Sr. VP of Corp. Strategy, Gen. Counsel & Sec. (Age 45)
  • Dr. Dietmar P. Berger M.D., Ph.D., Global Head of R&D (Age 56)

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $14.69.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $865.98 million. The biotechnology company earns $-290,980,000.00 in net income (profit) each year or ($5.67) on an earnings per share basis. Atara Biotherapeutics employs 321 workers across the globe.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is www.atarabio.com.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.